supp.fit

Nicotinamide Riboside: study protocols

25 study groups say how much Nicotinamide Riboside participants took a day. These are the doses the studies gave. They are not a recommendation.

Nicotinamide Riboside: what the research found →

Dose per serving from products

205 products in our catalogue print how much Nicotinamide Riboside a serving holds.

Most common: 250 mg to 500 mg, 51% of 205 products.

Dose per servingProducts
50 mg or less
9
50 mg to 100 mg
19
100 mg to 250 mg
24
250 mg to 500 mg
104
500 mg to 1 g
35
1 g to 2.5 g
14

Dose per serving from research

25 study groups in 16 studies say how much Nicotinamide Riboside participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 44% of 25 study groups.

Daily doseStudy groups
250 mg or less
1
250 mg to 500 mg
8
500 mg to 1 g
11
1 g to 2.5 g
4
over 2.5 g
1

Commonly used together

7 of 25 study groups took Nicotinamide Riboside with something else, but nothing that 3 or more different studies gave.

25 study groups

Study
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease
2023 · NR · Adults aged 35 to under 100 with idiopathic Parkinson’s disease and Hoehn and Yahr score below 4; ages in the enrolled group ranged from 52 to 78 years
3 g4 weeks10
Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial
2025 · NR treatment phase · Adults with Werner syndrome; mean age 47 years, 44.4% male
1 g26 weeks6
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
2024 · NR alone · Adults with peripheral artery disease; mean age 73.21 years in this arm; men and women
500 mg26 weeks28
Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease
2023 · NR · Adults aged 30–79 with chronic kidney disease (eGFR below 60 mL/min/1.73 m²) and 6-minute walking distance below 550 m
1 g6 weeks25
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
2024 · NR group · Older adults with mild cognitive impairment
1 g10 weeks—
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
2021 · CMA group, phase 3 · Adults aged 18–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization
2 g2 weeks229
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
2021 · CMA group, phase 2 · Adults aged 19–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization
2 g2 weeks71
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
2024 · NR + resveratrol · Adults with peripheral artery disease; mean age 70.73 years in this arm; men and women
500 mg26 weeks33
Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial
2025 · NR · Sedentary adults aged 55 years and older with hypertension
500 mg6 weeks19
Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial
2025 · NR + Ex · Sedentary adults aged 55 years and older with hypertension
500 mg6 weeks17
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults
2018 · NR (nicotinamide riboside) condition · Healthy men and postmenopausal women aged 55–79 years
1 g6 weeks30
Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin
2023 · Nicotinamide riboside · Healthy adults, 65 ± 7 years old; 11 men and 11 women
1 g6 weeks22
The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans
2026 · NR · Healthy adults aged 18–50 years, male and female
1 g2 weeks17
Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial
2024 · NR group (lung-healthy controls) · Lung-healthy adults aged about 60 years or older, never-smokers with no history of lung disease
500 mg6 weeks10
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease
2022 · NR · Newly diagnosed, treatment-naive patients with Parkinson's disease
1 g30 days—
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
2019 · 100 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight
100 mg8 weeks35
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
2019 · 300 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight
300 mg8 weeks35
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
2019 · 1000 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight
1 g8 weeks35
Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial
2024 · NR group (patients with COPD) · Adults aged 60 years or older with non-eosinophilic COPD who were former smokers
500 mg6 weeks20
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans
2020 · NR supplementation · Men and postmenopausal women aged 45–65 with overweight or obesity (BMI 27–35), without active diseases
1 g6 weeks13
Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures
2019 · NR · Men aged 70–80 years, otherwise healthy and marginally overweight
1 g3 weeks12
Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
2020 · NRPT 250/50 mg (Step 1) · Hospitalized adults aged 18 years or older with acute kidney injury
500 mg2 days5
Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
2020 · NRPT 500/100 mg (Step 2) · Hospitalized adults aged 18 years or older with acute kidney injury
1 g2 days5
Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
2020 · NRPT 750/150 mg (Step 3) · Hospitalized adults aged 18 years or older with acute kidney injury
1.5 g2 days5
Nicotinamide riboside with pterostilbene (NRPT) increases NAD(+) in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
2020 · NRPT 1000/200 mg (Step 4) · Hospitalized adults aged 18 years or older with acute kidney injury
2 g2 days5